ProPhase Labs, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Earnings Per Share (Tables)

Earnings Per Share (Tables)

3 Months Ended

Mar. 31, 2024

Schedule of Basic and Diluted Net Loss Per Share

The following is a reconciliation of the weighted average number of common shares outstanding used in calculating basic and diluted net loss per share (in thousands):


	For the three months ended
	March 31, 2024		March 31, 2023
Net (loss) income - basic	$	(6,265)	$	550
Interest on unsecured convertible promissory note	—		60
Net (loss) income - diluted	$	(6,265)	$	610

Weighted average shares outstanding - basic	18,045		16,748
Diluted shares- Stock Options	—		22
Diluted shares- Stock Warrants	—		1,051
Unsecured convertible promissory note	—		240
Weighted average shares outstanding - diluted	18,045		18,061

Schedule of Anti-dilutive Securities Excluded from the Income Per Share Computation

The following table represents the number of securities excluded from the income per share computation as a result of their anti-dilutive effect (in thousands):


	For the three months ended
Anti-dilutive securities	March 31, 2024	March 31, 2023
Common stock purchase warrants	376	581
Stock options	4,452	870

Anti-dilutive securities	4,828	1,451